

Halle (Saale), Munich, June 23rd, 2009

Joint press release of Scil Proteins GmbH and Scil Technology GmbH

New financial director at the Scil Group

Halle (Saale), Munich, 23.06.09. Scil Proteins GmbH and Scil Proteins Production GmbH in Halle (Saale) are growing rapidly and therefore are going to extend their management. New financial director of both corporations is now Frank Ubags. Ubags replaces Christian Nafe, who so far held the position within the Scil-corporation in Halle as well as within Scil Technology in Munich. Because of the increasing importance of strategic alliances Nafe is going to concentrate his efforts on the Scil-site in Munich. The Scil-companies at Halle have new production site for therapeutic proteins. In April Scil Proteins Production received the certificate of quality for good manufacturing practice (GMP) as well as the permission for producing the anti-thrombotic drug substance "reteplase". Within the last two years the number of employees at the sites in Halle has increased from 35 to 90.

About the persons:

Frank Ubags, amongst other things, was CFO at Rhein Biotech (Maastricht, Düsseldorf). To begin with he was responsible for the initial public offering of the corporation as well as for several acquisitions of companies in Asia and South America. In 2002 he conducted the sale to Berna Biotech (Bern) and as CEO he was responsible for the sale of Rhein Biotech Düsseldorf to Dynavax (USA) in 2006. Later on he held the post of CFO at Kiadis Pharma (Amsterdam, Montreal). Before joining Scil Proteins, he worked as an independent consultant for a short period of time.

Christian Nafe, who has been working for Scil since 2000, was initially responsible for the implementation of the controlling unit. Since 2003 he held the post of CFO in all three Scil Biotech Companies at Halle and Munich and took an

Scil Proteins GmbH

Heinrich-Damerow-Straße 1
06120 Halle

Tel. + 49 (0) 345-27 99 6330

Fax + 49 (0) 345-27 99 6332

www.scilproteins.com

info@scilproteins.com

Geschäftsführer

Dr. Ulrike Fiedler

Amtsgericht Stendal

HRB 212705

Deutsche Bank Halle

BLZ 860 700 00

Konto 5 250 006

USt-Id.-Nr. DE 207778413

Steuer-Nr. 110/105/04750

essential part in setting up the corporations and in developing them further. In addition, he took a main part in the corporation's financial rounds as well as in its licence and production deals. Intermittently, he took on the post as interim executive director at Scil Diagnostics for a two year period.

About the companies:

Scil Proteins specialises in researching, developing and producing recombinant proteins. Scil Proteins is actively involved in two business areas: Scil Proteins Pharma develops innovative biopharmaceutical products on the basis of the Affilin® technology, and the Scil Proteins Production manufactures recombinant proteins for research, clinical studies and the market.

Scil Technology GmbH develops unique biomaterials that integrate bone or cartilage growth factors and synthetic scaffolds or implants. Applying its proprietary technology, the Company combines the very best of prosthetic and bone augmentation technologies with pioneering regenerative medicine. What sets Scil Technology further apart is its proprietary protein coating technology that allows for a highly stable and homogeneous bonding of growth factors to scaffolds or implants. Scil Technology is using this expertise to develop applications for dentistry and orthopaedics.

Contact Scil Proteins GmbH:

Dr. Ole Fuetterer

Director of Business Development

Heinrich-Damerow-Straße 1

06120 Halle (Saale)

Germany

Phone: +49 (0) 3 45 478 03 03

Fax: +49 (0) 3 45 478 03 01

Email: Ole.Fuetterer@scilproteins.com

Internet: www.scilproteins.com

Contact Scil Technology GmbH:

Scil Technology GmbH

Fraunhoferstraße 15

82152 Martinsried

Germany

Phone: +49 (0) 89 85 65 18 00

Fax: +49 (0) 89 85 65 18 18

Email: info@sciltechnology.com

Internet: www.sciltechnology.com